Premier Path Wealth Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Premier Path Wealth Partners’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$282K	Hold	20,265	–	–	0.04%	354
2025 Q4	$245K	Hold	20,265	–	–	0.03%	361
2025 Q3	$275K	Hold	20,265	–	–	0.04%	345
2025 Q2	$130K	Hold	20,265	–	–	0.02%	384
2025 Q1	$71.7K	Buy	+20,265	New	+$72.1K	0.01%	372
2024 Q4	–	Sell	-20,265	Closed	-$65.7K	–	370
2024 Q3	$65.7K	Buy	+20,265	New	+$45.6K	0.01%	364
2024 Q2	–	Sell	-20,265	Closed	-$57.6K	–	369
2024 Q1	$57.6K	Hold	20,265	–	–	0.01%	343
2023 Q4	$298K	Buy	+20,265	New	+$311K	0.07%	261

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Premier Path Wealth Partners's AMLX Position: Q1 2026 in Review

Premier Path Wealth Partners held its Amylyx Pharmaceuticals (AMLX) position steady in Q1 2026 at 20,265 shares worth $282K. The position accounts for 0.04% of the portfolio, ranked #354.

Premier Path Wealth Partners first reported a position in AMLX in Q4 2023 and has held it in 8 quarters since. The position peaked at $298K in Q4 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Premier Path Wealth Partners held 20,265 shares of Amylyx Pharmaceuticals worth $282K as of Q1 2026.
Premier Path Wealth Partners left its Amylyx Pharmaceuticals share count unchanged in Q1 2026.
Amylyx Pharmaceuticals made up 0.04% of Premier Path Wealth Partners's portfolio in Q1 2026, its #354 holding.
Premier Path Wealth Partners first reported a position in Amylyx Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
Premier Path Wealth Partners's Amylyx Pharmaceuticals position peaked at $298K in Q4 2023.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Premier Path Wealth Partners's 13F filing for Q1 2026, filed 23 Apr 2026.